Cancer Research UK is partnering with the Royal Marsden NHS Foundation Trust and Guardant Health to make circulating tumor DNA (ctDNA) testing freely available to hundreds of patients with advanced solid tumors across the UK’s Experimental Cancer Medicine Centre (ECMC) network. CRUK is supporting the initiative with a grant of undisclosed size. The program is designed as a proof of concept for expanding testing capacity, with a goal of making at least 500 Guardant360 Liquid CDx tests available through ECMCs over the next few months. The plan aligns with England’s National Cancer Plan and is intended to support ctDNA profiling for precision medicine trials. Guardant360 Liquid CDx analyzes genomic and epigenomic markers in ctDNA to identify actionable mutations that can guide targeted therapy decisions. Guardant noted that the assay recently received FDA approval. Royal Marsden previously used Guardant-linked ctDNA testing through Marsden360, and the new collaboration extends access to ECMC patients, aiming to reduce bottlenecks in molecular diagnostics and broaden participation in liquid biopsy-enabled studies.